How to Value a Large Hospice Company (Multi-State Operators)

Hospice is one of the most active M&A verticals in healthcare, and large hospice platforms command some of the highest multiples in the entire health services sector. When UnitedHealth Group acquired Amedisys for roughly $3.3B in 2024, it valued the combined hospice and home health platform at approximately 15x EBITDA. That's not an outlier — it's the market for scaled hospice operations.

I've advised on hospice transactions from single-location agencies to multi-state platforms, and the valuation dynamics are fundamentally different at scale. A single-location hospice selling at 6-9x EBITDA operates in a different market than a 500+ ADC platform selling at 12-18x. Here's why, and what drives the premium.

Why Scale Commands a Premium in Hospice

Hospice economics reward scale more than almost any other healthcare subsector. The reasons are structural.

Medicare is the payer.Roughly 90% of hospice revenue comes from Medicare. That means revenue is predictable, reimbursement rates are published annually, and there's no commercial insurance negotiation. But it also means every hospice operator is subject to the same regulatory framework — and larger operators can absorb compliance costs more efficiently.

Referral network density. Hospice admissions come from hospital discharge planners, skilled nursing facilities, physician practices, and increasingly from health plan care management teams. A multi-state platform with relationships across dozens of hospital systems generates a steady, diversified referral pipeline that a single location simply cannot match.

State licensing creates moats. Several states operate Certificate of Need (CON) programs for hospice, meaning you cannot open a new hospice agency without state approval. In CON states like Alabama, Georgia, Kentucky, North Carolina, South Carolina, Tennessee, and Virginia, existing licenses are extraordinarily valuable because new competition is legally restricted. A platform with licenses across multiple CON states has assembled a portfolio of regulatory moats that took years and significant capital to build.

The Key Valuation Metrics for Large Hospice Platforms

Average Daily Census (ADC).This is the North Star metric. ADC measures the average number of patients on service on any given day. A single-location hospice might run 80-150 ADC. A platform-grade operator runs 500+ ADC across multiple locations. The largest operators — VITAS (owned by Chemed Corporation), Kindred at Home (now Gentiva under Humana), and Enhabit Home Health & Hospice — run thousands of ADC.

Revenue per patient day. Medicare hospice reimbursement in 2026 runs approximately $200-215 for routine home care (the vast majority of patient days), with higher rates for continuous home care ($1,100+/day), inpatient respite (~$500/day), and general inpatient care (~$1,100/day). The mix of care levels directly impacts revenue per patient day.

Length of stay (LOS). This is where hospice valuation gets nuanced. Average length of stay for hospice is approximately 70-90 days, but the median is much shorter (around 18-25 days) because a small percentage of long-stay patients skew the average. Buyers scrutinize LOS distribution because it signals both the quality of the referral pipeline and potential regulatory risk.

Quality metrics. CMS publishes star ratings for hospice agencies based on the Hospice CAHPS survey (family satisfaction) and quality reporting program measures. Four and five-star agencies command premium multiples because they face lower regulatory scrutiny and win more referrals from hospital systems that track quality scores. Sub-three-star agencies carry a valuation discount — and an operational remediation project for the buyer.

EBITDA margin.Well-run large hospice platforms generate 15-22% EBITDA margins. The key expense drivers are clinical labor (nurses, aides, social workers, chaplains), pharmacy costs, and G&A overhead. Platforms that have centralized their back office and pharmacy procurement run at the higher end of the margin range.

Regulatory Risk: The Elephant in Every Hospice Deal

No discussion of hospice valuation is complete without addressing regulatory risk. Hospice has faced intensifying scrutiny from CMS, the OIG (Office of Inspector General), and the DOJ over the past five years. The issues that keep buyers' legal teams up at night:

Medicare hospice cap. CMS sets an annual per-beneficiary cap on hospice payments (approximately $33,000-$34,000 in 2026). Agencies whose average Medicare payment per beneficiary exceeds this cap must repay the excess. Large platforms with long average LOS are most exposed. During diligence, buyers model cap liability exposure across every location — a cap overpayment of $2M is a direct hit to enterprise value.

GIP scrutiny. General Inpatient Care (GIP) reimburses at roughly 5x the routine home care rate. CMS and OIG have specifically targeted operators with unusually high GIP utilization. If your GIP days exceed 5-7% of total patient days, expect aggressive diligence questions and potential valuation adjustments.

Compliance history.Any prior OIG investigation, DOJ settlement, False Claims Act action, or state survey deficiency is going to be scrutinized exhaustively. The Amedisys acquisition, for example, involved a thorough review of the company's prior DOJ settlement history. A clean compliance record is one of the most valuable attributes a hospice platform can have.

Proposed rule changes. CMS has proposed various reforms to hospice payment including potential site-neutral payments and changes to the hospice benefit period structure. Buyers discount projected future cash flows for regulatory uncertainty — the more exposed your revenue model is to potential reforms, the lower your multiple.

The Diversification Premium: Hospice + Home Health + Palliative

The highest multiples in this space go to platforms that have diversified across the post-acute care continuum. A hospice-only platform at 500 ADC might trade at 12-14x EBITDA. The same platform with a complementary home health operation and a palliative care program might command 15-18x.

The logic is straightforward. Home health patients are a natural feeder into hospice. Palliative care captures patients who aren't yet hospice-eligible but will be in 3-12 months. A platform that manages patients across all three service lines captures more revenue per patient, has longer patient relationships, and is more valuable to health plan and hospital system partners.

Enhabit's spin-off from Encompass Health was partially predicated on this thesis — a combined home health and hospice platform with geographic overlap creates referral synergies that pure-play operators lack.

Named Transactions and Benchmarks

Recent large hospice transactions provide concrete valuation benchmarks:

• UHS / Amedisys (2024): ~$3.3B, approximately 15x EBITDA for a combined hospice/home health platform with ~$2.2B revenue
• Humana / Kindred at Home (2021): ~$5.7B for the nation's largest home health and hospice provider, roughly 16-18x EBITDA at the time
• VITAS (Chemed subsidiary): Chemed trades at ~14-16x EBITDA, with VITAS as the dominant value driver generating $1.4B+ revenue
• Mid-market platforms (200-500 ADC): Typically transacting at 10-14x EBITDA depending on geography, quality scores, and growth trajectory

What Buyers Are Looking for in 2026

The buyer universe for large hospice platforms includes health systems (looking for downstream integration), managed care organizations (Humana, UnitedHealth), large PE-backed platforms seeking geographic expansion, and publicly traded home health/ hospice companies.

What consistently differentiates a 12x exit from a 16x exit:

• Clean compliance history with no OIG/DOJ exposure
• Four or five-star quality ratings across the majority of locations
• CON state licenses that are difficult or impossible to replicate
• Diversified referral sources (no single hospital system accounting for more than 15% of admissions)
• Management team with depth (not founder-dependent)
• Consistent ADC growth of 5-10% annually on a same-store basis

The Bottom Line

Large hospice platforms are premium assets in healthcare M&A, but the valuation is only as strong as the compliance foundation underneath it. The demographics — 10,000 baby boomers turning 65 every day — make the demand story compelling. The regulatory environment makes the execution story complex. Sellers who invest in quality, compliance, and management infrastructure before going to market consistently achieve top-quartile outcomes. Those who cut corners on compliance or ignore quality metrics discover that the discount is severe and non-negotiable.